Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,John Allan, MD

Panelists discuss how real-world data on the incidence of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) compare with clinical trial findings as well as the most critical patient-related risk factors for developing these toxicities.

EP: 1.ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP: 2.Emerging Data for Odronextamab in DLBCL

EP: 3.Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP: 4.Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP: 5.ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

EP: 6.MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

Now Viewing

EP: 7.Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

EP: 8.Key Strategies for Preventing CRS and ICANS

Video content above is prompted by the following:

How do real-world data on the incidence of CRS and ICANS compare with clinical trial findings? (Dr Allan )
What are the most critical patient-related risk factors for CRS and ICANS? (Dr Graff)